On central adjudication , incidence of venous thromboembolism was 19.2 % ( 53 of 276 patients ) in the ximelagatran group and 25.7 % ( 67 of 261 patients ) in the warfarin group ( difference , -6.5 percentage points [ 95 % CI , -13.5 to 0.6 percentage points ] ; P = 0.070 ) .
